No. One-on-one discussions between potential proposers and the BIOGAMI team should be requested as sidebars during Proposers' Day.

Correct, BIOGAMI requires two indications. The indications may be one rare NDD and one non-rare, non-NDD, or one non-rare NDD and one rare non-NDD.

BIOGAMI is not prescriptive towards a breadth vs depth approach. Proposers should describe their methods and justify their choice towards achieving the end goal of a highly accurate computational tool that can be applied to any intrinsically disordered protein.

BIOGAMI is agnostic to both therapeutic modality as well as delivery technology.

BIOGAMI is not prescriptive with respect to specific IDR targets or clinical indications, so long as the requirements for neurodegenerative disease and non-neurodegenerative disease, and rare and non-rare disease are met as stipulated by the ISO. 

Although BIOGAMI does not have a clinical component within the program requirements, the ultimate goal of clinical translation is important. A clinician is not required, but could be part of a proposing team as a research member, consultant, or member of the Translation Advisory Board. 

No. The BIOGAMI ISO does not include an affordability/accessibility requirement.

Protein-protein interactions should be mapped with respect to the IDP of interest and identified in the context of misfolding/aggregation. Protein-protein interactions should inform both protein function and how key functions are lost through misfolding/aggregation. Conversely, new interactions formed could inform toxic gain of function based on conformational changes.

Per Section 2.5 of the ISO, BIOGAMI proposers must agree to openly share deidentified/sanitized data acquired through TA1 activities during the period of performance. This requirement, however, does not presuppose prior open-source data sharing.

No. BIOGAMI proposals must address two disease indications to be conforming. 

While solutions that modulate IDR folding to prevent aggregation are desired, BIOGAMI will consider solutions that modulate features of aggregated proteins to facilitate their dissolution or removal with emphasis on restoration of healthy protein function. Incremental improvements to existing therapies targeting downstream aggregates (passive immunotherapy, etc.) that do not build on novel BIOGAMI TA1 approaches to transform efficacy are out of scope. 

BIOGAMI is open to both intracellular and extracellular interventions. 

Per Table 3, BIOGAMI requires demonstration of efficacy in a pre-clinical animal model and preliminary safety studies to investigate off-target activity. 

Yes. BIOGAMI is considered protein targets within scope if they contain one or more disordered domains. Disorder across the entire length of the protein is not required. 

No, there is no maximum team size for BIOGAMI submissions. Teams should have the expertise and capacity to achieve the goals of the proposed work.

Yes, individuals may participate on more than one team and be listed on multiple submissions. There is no restriction on being part of multiple teams. 

The consortium agreement does not need to be signed prior to proposal submission, but it should be formalized by the time of award.

Section 2.8 of the BIOGAMI ISO describes the requirements for a multi-party teaming arrangement structure. The multi-party team generally chooses one member to act as the agent and/or lead member for administration and reporting purposes. There is no preference for the lead member to be a for-profit company or a research institution.

Section 2.8 of the BIOGAMI ISO describes the requirements for a multi-party teaming arrangement structure, which is distinct from the traditional NIH model. In this structure, leadership can change among team members based on expertise and project phase. The multi-party team generally chooses one member to act as the agent and/or lead member for administration and reporting purposes, but this agent does not need to be the lead performing organization. The ISO does not prescribe specific titles (such as Executive Director, Scientific Director, and Principal Investigator) for team leadership. Instead, proposals should clearly describe the anticipated leadership structure and changes throughout the program. The key is to demonstrate a flexible, dynamic team structure that meets the program’s requirements.

Teaming Profiles can be found at BIOGAMI Teaming | ARPA-H and will be updated on a regular basis. 

BIOGAMI is not prescriptive regarding team size and/or composition. Proposing teams should ensure that expertise across both Technical Areas is represented. 

Section 2.6 of the ISO describes commercialization requirements. Teams are strongly encouraged to demonstrate an active partnership with a designated commercial entity at the time of proposal, although this is not required. 

No, UARCs are not eligible to propose directly to BIOGAMI.

ARPA-H does not form teams or match partners directly. However, Proposers’ Days are designed to help interested organizations learn about the program and identify potential collaborators. We encourage you to use the event to meet others who may have complementary capabilities. You can also explore potential teams on the BIOGAMI teaming page.

No. BIOGAMI welcomes ideas from all proposers. 

ARPA-H can directly fund a foreign entity; however, ARPA-H will prioritize awards to entities that conduct funded work in the U.S., as per 42 USC § 290c(n)(1). Awards will not be made to entities organized under the laws of a covered foreign country, defined in the National Security Act of 1947 (50 U.S.C. § 3059) as Russia, Iran, North Korea, and China. Each solicitation defines eligibility and requirements so please review the solicitation for detailed instructions. For more information, see the International Affairs FAQs. 

There is no preference for an international entity performing as a prime contractor or subcontractor. It is dependent on the merits of the proposal and the qualifications of the proposer. However, the Agency does prioritize awards to entities that will conduct funded work in the United States as dictated per 42 U.S.C. 290c(n)(1), which could be achieved through collaboration with U.S. entities. Interested international partners may sign up on “teaming” pages on our website – linked from each program description page – which are provided to facilitate prospective performers forming teams with varied technical expertise to submit a proposal.   

• The Proposers’ Day will be held from 9:00 AM to 5:00 PM Eastern Time on February 20, 2026.  
• Doors open and webinar login begins for registered attendees at 8:30AM.  
• A final agenda, including order of Lightning Talks and Sidebars, will be emailed to registered attendees before the meeting.

No. Lightning talks can be presented either in person or virtually, but Proposer’s Day does not offer an option to play prerecorded videos.

The BIOGAMI audience will include ARPA-H staff and contractors, other US Government employees, and the potential performer community – including individuals from academia and industry. 

BIOGAMI Proposers' Day is a hybrid event with both virtual and in-person attendance options. A recording of Proposers' Day will be posted to the BIOGAMI website a few days following Proposers' Day.

No. One-on-one discussions between potential proposers and the BIOGAMI team should be requested as sidebars during Proposers' Day.

No, all the required information for Proposers' Day is requested within the registration portal.

Yes. Virtual attendees may present their Lightning Talk through the webinar, or they may delegate to an in-person attendee from their team.

Yes. Sidebars for virtual attendees will be scheduled for the following Monday, February 23rd.

Yes, a template for the Lightning Talk can be found at SAM.gov as part of ARPA-H-SN-26-147.

BIOGAMI Proposer’s Day serves as a means for potential proposers to meet and determine if they would like to form a team. Participation at Proposers’ Day is not required, however; teams may include members who did not attend. 

If attendance on February 20th is not feasible either in person or virtually, an interested party can view a recording of Proposers’ Day that will be posted to the BIOGAMI webpage a few days afterwards.

Lightning Talks are useful to facilitate teaming, as potential proposers can share their capabilities and their gaps with other attendees. 

Attendees will be notified via email within 10 days of their registration.

For an ARPA-H Proposers’ Day, the sidebar is a short, one-on-one meeting between a potential proposer (or team) and ARPA-H program staff, usually the Program Manager (PM) and their team. In practice, a sidebar is used to: Clarify fit to the program vision; Ask focused technical questions; Get high-level feedback on ideas; Network and refine teaming strategies.  Sidebars are not: Formal proposal reviews; A venue for getting an “advance decision” on funding; A place to share proprietary or selection-sensitive details of a proposal. They’re meant to help you better understand the program and sharpen your approach before you decide whether and how to submit. 

The Lightning Talk template provides useful guidelines for the types of information to be conveyed, but the specific template is not required. As a reminder, Lightning Talks are limited to 1 slide and 3 minutes. 

Yes, the Agenda will be sent to all attendees by Thursday, February 19, 2026. 

Yes, if registered for virtual attendance, you can tune-in at your convenience. A recording of Proposer’s Day will be posted to the BIOGAMI webpage and ARPA-H YouTube a few days after the meeting.   

Yes, there is time set aside for Q&A at the meeting.  Alternatively, you can submit questions to https://solutions.arpa-h.gov/Ask-A-Question/. 

The BIOGAMI Solution Summary submission deadline is fixed. You may submit a Solution Summary even if your SAM.gov registration is not yet complete.

BIOGAMI anticipates multiple awards.

In accordance with ISO Section 5.3, CRITERIA 4: Assessment of Proposed Cost/Price, proposers are encouraged to submit a fully justified budget that is appropriate for the scope, complexity, and risk of their proposed technical approach. ARPA-H will evaluate the reasonableness and value of the proposed cost in the context of the work to be accomplished, rather than against a predetermined budget amount or range.

The multi-party team will be structured through a single teaming agreement signed by all team members. The OT award is issued to the entire multi-party team, with all members as parties to the agreement. One member may act as the agent for administration, but the award is not structured as a traditional prime/sub-performer contract.